TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02316769

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: King Vision video laryngoscope
Description: Patient intubated with the King Vision Video Laryngoscope

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: McGrath MAC video laryngoscope
Description: Intubation with the McGrath MAC video laryngoscope
Study: NCT03581084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Research participants that meet the study inclusion criteria will be admitted to a medical-surgical ward in Moffitt-Long Hospital (UCSF Medical Center) for 6 days and 5 nights and treated with an inhaled mixture of NAC and albuterol four times per day spaced at 4 to 6 hours apart.
Study: NCT01797679

Intervention type: OTHER
Group type: OTHER
Intervention: Strength Training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Study: NCT02174432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalbuphine HCl ER
Description: nalbuphine HCl ER BID for up to 50 weeks
Study: NCT03814798

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IGSC 20% daily push versus every 2 weeks pump
Description: IGSC 20% syringe daily push dosing for 16 weeks followed by every 2 weeks pump dosing for 16 weeks or the reverse sequence

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IGSC 20% daily push versus once a week pump
Description: IGSC 20% syringe daily push dosing for 16 weeks followed by once weekly ambulatory pump administration dosing for 16 weeks or the reverse sequence

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IGSC 20% daily push versus 2 times per week pump
Description: IGSC 20% syringe daily push dosing for 16 weeks followed by 2 times/week ambulatory pump administration on preselected days (eg, Monday and Thursday) not less than 3 days apart for 16 weeks or the reverse sequence

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IGSC 20% 150 mg/kg
Description: loading dose of IGSC 20% consisting of 5 consecutive daily doses of 150 mg/kg/day (Week 0, Days 1-5) followed by weekly infusions of IGSC 20% 150 mg/kg starting Week 1 (Day 8) through Week 32 using an infusion SC pump
Study: NCT00441090

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets 2.5, 5, 10 and 20 mg taken orally once daily for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag tablets
Description: Avatrombopag tablets 2.5, 5, 10 and 20 mg taken orally once daily for 28 days.
Study: NCT03630822

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychiatric Advanced Directive
Description: The patient completes a questionnaire to express in advance his wishes regarding his future care in psychiatry.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: standardized maintenance with the patient
Study: NCT02017054

Intervention type: OTHER
Intervention: Cath
Description: No intervention - registry
Study: NCT03324893

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [F-18]-FCH PET/MRI
Description: Subjects will undergo the \[F-18\]-FCH PET/MRI within three months prior to scheduled parathyroidectomy.
Study: NCT03240731

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bone marrow transplant
Description: haploidentical bone marrow transplant
Study: NCT03058341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Monitoring and other anaesthetic procedures including the management of hypertension and hypotension will be the same as group S. The only difference is that induction and maintenance of general anaesthesia will be conducted using total intravenous infusion of propofol. Sevoflurane will not be used, and oxygen and air would be given to provide a FiO2 of 30-50%.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sevoflurane
Description: Propofol 1.5-3mg/kg, remifentanil 0.5-1mcg/kg, and rocuronium 0.6-1mg/kg or atracurium 0.5mg/kg will be used intravenously (IV) for induction of general anaesthesia. Otrivin can be applied nasally at the discretion of the anaesthetist. Intubation would be performed after induction of general anaesthesia. General anaesthesia monitoring will be used. Sevoflurane, air and oxygen will be used for maintenance of general anaesthesia. FiO2 will be kept between 35-50%. BIS monitoring will be applied and level of anaesthetia will be titrated to keep a BIS value of 40-60. Intravenous remifentanil infusion between 0.1-0.25mcg/kg/min will be given and this will be titrated to optimal haemodynamic parameters. Muscle relaxants can be given during the operation as required.
Study: NCT01241149

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: anti-reflux surgery
Description: Anti-reflux surgery (Laparoscopic Nissen Fundoplication)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anti-reflux surgery
Description: Anti-reflux surgery (Laparoscopic Nissen Fundoplication)
Study: NCT03831243

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: Treatment will be prescribed to the periphery of the target, i.e. 80% of the dose should cover 95% of the PTV. The organ at risk (OAR) dose constraints will be in accordance with the recommendations from the report of the American Association of Physicists in Medicine (AAPM) task group 101. Image-guidance will consist of cone-beam CT in combination with 6 degrees of freedom corrections using robotic couch.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3D-conformal radiotherapy
Description: In the standard setting, 95% of the PTV should receive 95% of the prescribed dose while near maximum dose (Dnear-max) in the PTV should not exceed 107%. Image-guidance will consist of portal images showing the relevant bony anatomy.
Study: NCT04040309

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRGF injection
Description: Plasma rich in growth factors will be prepared following the protocol described by E. Anitua. 9 ml of patients venous blood will be taken into one tube with 3,8% sodium citrate used as an anticoagulant. The blood then will be centrifuged (PRGF Centrifuge System, Biotechnology Institute, Vitoria, Spain) at room temperature for 8 min at 1800 rpm. After centrifugation 1 ml of 2nd plasma fraction will be collected by using a pipet. To activate plasma 10% calcium chloride will be used immediately before injecting plasma into the trigger point in the masseter muscle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine injection
Description: 1 ml 2 % Lidocaine will be injected into the trigger point in the patient's masseter muscle.
Study: NCT01080222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir
Description: tablet, 1125-mg, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir
Description: tablet, 1125-mg, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir
Description: tablet, 1125-mg, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir
Description: tablet, 1125-mg, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir
Description: tablet, 1125-mg, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir
Description: tablet, 1125-mg, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-222
Description: capsule, 100-mg, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-222
Description: capsule, 100-mg, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablet, 1000-mg for subjects weighing \<75-kg or 1200-mg for subjects weighing ≥75-kg, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablet, 1000-mg for subjects weighing \<75-kg or 1200-mg for subjects weighing ≥75-kg, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablet, 1000-mg for subjects weighing \<75-kg or 1200-mg for subjects weighing ≥75-kg, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablet, 1000-mg for subjects weighing \<75-kg or 1200-mg for subjects weighing ≥75-kg, twice daily

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peginterferon-alfa-2a
Description: subcutaneous injection, 180-mcg, once weekly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peginterferon-alfa-2a
Description: subcutaneous injection, 180-mcg, once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-222
Description: capsule, 400-mg, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-222
Description: capsule, 400-mg, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-222
Description: capsule, 400-mg, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-222
Description: capsule, 400-mg, twice daily
Study: NCT01445925

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation (PVI)
Description: Using a 4mm irrigated tip radiofrequency ablation catheter a series of lesions \>2 mm outside pulmonary vein (PV) ostia will be made to encircle and electrically isolate the pulmonary veins in two ipsilateral pairs (wide area circumferential ablation, WACA). A 20-pole PV mapping catheter will be used to confirm electrical isolation. If the patient is in atrial fibrillation at this stage, sinus rhythm would be restored with electrical cardioversion and PVI would be confirmed in sinus rhythm

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation + linear lesions
Description: Using a 4mm irrigated tip radiofrequency ablation catheter a series of lesions \>2 mm outside PV ostia will be made to encircle and electrically isolate the pulmonary veins in two ipsilateral pairs (wide area circumferential ablation, WACA)34. A 20-pole PV mapping catheter will be used to confirm electrical isolation. Once PVI has been achieved, patients will go onto to receive additional linear ablation lesions. These will include a left atrial roof line, mitral isthmus line, (including ablation inside the coronary sinus if necessary), and ablation on the cavotricuspid isthmus. If the patient is in atrial fibrillation at this stage, the acute end-point would be signal obliteration at the ablated area. Once sinus rhythm is restored with electrical cardioversion, PVI would be confirmed in sinus rhythm and conduction block across the LA roof line, Mitral line and CTI will then be verified with appropriate pacing manoeuvres.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Substrate modification
Description: at least 6 weeks therapy with oral amiodarone prior to the ablation procedure and 6 weeks post.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacological Substrate modification
Description: at least 6 weeks therapy with oral amiodarone prior to the ablation procedure and 6 weeks post.
Study: NCT04504331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infigratinib
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infigratinib
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infigratinib
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Oral Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Oral Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Oral Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omnipaque 350
Description: IV contrast agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omnipaque 350
Description: IV contrast agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omnipaque 350
Description: IV contrast agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iopamidol
Description: IV contrast agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iopamidol
Description: IV contrast agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iopamidol
Description: IV contrast agent

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT)
Description: Computed tomography (CT) to assess disease state using Iopamidol and/or Omnipaque 350.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT)
Description: Computed tomography (CT) to assess disease state using Iopamidol and/or Omnipaque 350.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT)
Description: Computed tomography (CT) to assess disease state using Iopamidol and/or Omnipaque 350.
Study: NCT01980238

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cannula ileostomy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: loop ileostomy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LAR

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LAR
Study: NCT02608398

Intervention type: OTHER
Intervention: no intervention
Description: NO intervention by the research group - this is an observational study. urine samples simply collected as children lose weight on their diet and exercise camp
Study: NCT04436666

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: motivational video production through virtual reality glasses
Description: Music-funded, park, nature and seaside walks, submarine, museum, with virtual reality glasses (Bobo VR Z4 Binocular Glasses and 5.7 inch 1440x2560 pixel display resolution, China) for 10 minutes to diabetic patients before blood glucose measurement and insulin injection The videos that the patient wants to watch will be watched from videos such as his trip Studies have indicated that these videos are relaxing environments, and motion videos should not be watched to reduce nausea and vomiting.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice Application
Description: Before the blood glucose measurement and insulin injection, patients with diabetes will be given ice for 5 minutes. It is planned to apply ice cubes in liquid-proof ice bags.
Study: NCT01161979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: Zonisamide capsules 100 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonegran
Description: Zonegran Capsules 100 mg of EISAI INC
Study: NCT02146313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMUC4064A
Description: Participants will receive escalated DMUC4064A dose or RP2D, as a single agent by intravenous (IV) infusion q3w on Day 1 of each cycle (21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMUC4064A
Description: Participants will receive escalated DMUC4064A dose or RP2D, as a single agent by intravenous (IV) infusion q3w on Day 1 of each cycle (21 days).
Study: NCT03575572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine is an alkaloid approved in 1961 for the use in Familial Mediterranean Fever in adults and children 4 years of age or older. It has been widely used for decades in other indications, such as Gout, recurrent pericarditis, pericardial effusions and other inflammatory diseases. This drug is commercially available and is approved in children 4 years and older.
Study: NCT02328209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: 0.5mg/0.05ml, intravitreal injection, frequency: each 8 or 12 weeks
Study: NCT03604653

Intervention type: DEVICE
Intervention: HIPEC
Description: Heated chemotherapy is pumped into the abdomen and circulated for 90 minutes

Intervention type: DEVICE
Intervention: HIPEC
Description: Heated chemotherapy is pumped into the abdomen and circulated for 90 minutes

Intervention type: DEVICE
Intervention: HIPEC
Description: Heated chemotherapy is pumped into the abdomen and circulated for 90 minutes

Intervention type: DEVICE
Intervention: HIPEC
Description: Heated chemotherapy is pumped into the abdomen and circulated for 90 minutes

Intervention type: DRUG
Intervention: Mitomycin c
Description: MMC 30mg@ T0, 10mg@T45 min

Intervention type: DRUG
Intervention: Mitomycin c
Description: MMC 30mg@ T0, 10mg@T45 min

Intervention type: DRUG
Intervention: CDDP 50
Description: 50mg/m2@T0
Study: NCT04551885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent
Study: NCT03604653

Intervention type: DRUG
Intervention: CDDP 50
Description: 50mg/m2@T0

Intervention type: DRUG
Intervention: CDDP 75
Description: 75mg/m2@T0

Intervention type: DRUG
Intervention: Doxorubicin
Description: 15mg/m2@T0
Study: NCT04551885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Biologic response modifier
Study: NCT01606566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphinex induced PCI of bleomycin
Description: Intravenous administration of 0.25 mg/kg Amphinex (day 0) followed by intravenous administration of bleomycin (15000 IU/m2, day 4) and laser light application (3 hours (+/- 1 hour) after bleomycin administration).
Study: NCT02962011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knotless barbed suture
Description: uterine incision closure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: polyglactin 910
Description: uterine incision closure
Study: NCT00901368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOSTER
Description: CHF1535 (beclometasone dipropionate 100 µg plus formoterol 6 µg) pMDI aerosol via HFA-134a propellant 2 inhalations b.i.d. (daily dose 400 µg + 24µg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide
Description: Fluticasone 250 µg + salmeterol 50 µg DPI (Seretide® Diskus®) 1 inhalation b.i.d. (daily dose 500+100 µg)
Study: NCT05751629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab was administered.
Study: NCT02146313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMUC4064A
Description: Participants will receive escalated DMUC4064A dose or RP2D, as a single agent by intravenous (IV) infusion q3w on Day 1 of each cycle (21 days).
Study: NCT00657488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide 100mg/day or 400 mg/day at bed time during one year
Study: NCT01448564

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laser therapy
Description: The therapeutic effects of low intensity lasers are: (i) analgesic and anti-inflammatory, (ii) regeneration, (iii) tissue healing and (vi) recovery from muscle fatigue.
Study: NCT00657488

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Thalidomide 100mg/day or 400 mg/day at bed time during one year
Study: NCT01448564

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo laser therapy
Description: The application of laser therapy will be a low intensity laser.
Study: NCT01116492

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single incision laparoscopic cholecystectomy
Description: One port placed through the umbilicus

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Standard 4 port laparoscopic cholecystectomy
Study: NCT02192970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT00897130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacytidine
Description: Azacitidine will be given at a dose of 75mg/sqm subcutaneous daily for 5 consecutive days every 28 days (every month) for a total of 8 courses. 5-Aza dosages will be adjusted
Study: NCT04012060

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limited access aortic valve replacement.
Description: Limited access aortic valve replacement through partial upper hemisternotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional aortic valve replacement
Description: Aortic valve replacement through full median sternotomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional aortic valve replacement
Description: Aortic valve replacement through full median sternotomy
Study: NCT03406546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine was used as a sedation agent with less side effect on respiratory system.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil was used to prevent cough induced by bronchoscopy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal mask
Description: Laryngeal mask was used to ensure respiration function during general anesthesia.
Study: NCT02856113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin Benzoate
Description: Alogliptin benzoate tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Alogliptin placebo-matching tablets.
Study: NCT03261128

Intervention type: OTHER
Intervention: Self-questionnaire
Description: Filling of a self-questionnaire before each chemotherapy cure
Study: NCT03951038

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCIA group
Description: The formula of the PCIA included tramadol 800 mg, flurbiprofen axetil 100mg with saline added up to a volume of 80 ml in total. The PCIA pump was set up with a 5 ml loading dose, a 2 ml bolus dose, a 15 min lockout interval and background infusion at a rate of 1 ml/h.
Study: NCT00481156

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Study: NCT03951038

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral TLIPB group
Description: both sides of the spine, a single injection of ropivacaine by nerve stimulating needle under ultrasound-guided between the longissimus and iliocostalis muscles .~The regimen of Lateral TLIPB group is0.2% 20ml ropivacaine and the regimen of PCIA is same with PCIA group.
Study: NCT02202746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucitanib
Description: Lucitanib is a potent, orally available selective inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors (FGFR1-3), vascular endothelial growth factor receptors (VEGFR1-3), and platelet-derived growth factor receptors alpha and beta (PDGFR alpha and beta)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucitanib
Description: Lucitanib is a potent, orally available selective inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors (FGFR1-3), vascular endothelial growth factor receptors (VEGFR1-3), and platelet-derived growth factor receptors alpha and beta (PDGFR alpha and beta)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucitanib
Description: Lucitanib is a potent, orally available selective inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors (FGFR1-3), vascular endothelial growth factor receptors (VEGFR1-3), and platelet-derived growth factor receptors alpha and beta (PDGFR alpha and beta)
Study: NCT00481156

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Social Skills Training